BioMaxima S.A. (WSE:BMX)

Market Cap	39.79M -31.7%
Revenue (ttm)	60.90M +15.2%
Net Income	105.00K -80.4%
EPS	0.02 -84.3%
Shares Out	4.19M
PE Ratio	378.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	906
Open	9.49
Previous Close	9.49
Day's Range	9.39 - 9.49
52-Week Range	9.30 - 14.75
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About BioMaxima

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in v...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 135
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2025, BioMaxima's revenue was 60.90 million, an increase of 15.24% compared to the previous year's 52.85 million. Earnings were 105,000, a decrease of -80.37%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error